Endothelial Derived Hyperpolarization Factor and Regulation of Cerebral and Muscle Blood Flow

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

Most cardiometabolic diseases are characterized by increased muscle sympathetic nerve activity (MSNA) during rest and exercise which contributes to poor health outcomes. In healthy humans during muscle contraction, there is a blunting of skeletal muscle vascular responsiveness to increases in MSNA. However, the exact mechanisms involved are unknown although, best evidence suggests that the mechanism is endothelium derived, but nitric oxide (NO) and prostaglandin (PG) independent. Endothelium-derived hyperpolarizing factor (EDHF) is a NO and PG independent vasodilator in both cerebral and skeletal muscle circulations, however, it is unknown if EDHF contributes to vascular responsiveness during elevated MSNA. The application of lower body negative pressure (LBNP) is a safe and non-invasive manipulation that can be used to increase MSNA causing vasoconstriction in humans. Therefore, the purpose of this experiment is to determine if acute inhibition of EDHF alters central and peripheral vascular responses to LBNP at rest and during dynamic exercise. Thereby, providing evidence by which EDHF contributes to vascular control in healthy humans and identify it's potential as a therapeutic target for cardiometabolic diseases that are characterized by elevated MSNA

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 30
Healthy Volunteers: t
View:

• Normotensive (systolic blood pressure \< 130 mmHg and/or diastolic blood pressure \< 85 mmHg) individuals

• Individuals free of cardiovascular disease and metabolic disease

• Individuals free of any form of autonomic dysfunction

• Individuals with a BMI under 30 kg/m²

• Women that are premenopausal with a regular menstrual cycle (26-30 days)

Locations
United States
Oklahoma
Department of Health and Exercise Science
RECRUITING
Norman
Contact Information
Primary
Jeremy M Kellawan, PhD
kellawan@ou.edu
4053259028
Time Frame
Start Date: 2022-02-19
Estimated Completion Date: 2025-05
Participants
Target number of participants: 30
Treatments
Experimental: fluconazole
fluconazole tablet/pill 150 mg, single acute dose
Placebo_comparator: Placebo
250 mg pill microcrystalline Cellulose, single acute dose
Related Therapeutic Areas
Sponsors
Leads: University of Oklahoma

This content was sourced from clinicaltrials.gov